Osteoporosis and inflammation;Osteoporose e inflamação

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 123-132

  Lacativa, Paulo Gustavo Sampaio ^a   de Farias, Maria Lucia Fleiuss ^b  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Arthritis; Inflammation; Interleukin 1; Lupus erythematosus; Osteoporosis; Rheumatoid; Systemic; Tumor necrosis factor alpha

Indexed keywords

EID: 77952714422     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000200007     Document Type: Article

References (56)

1. Mundy GR. Osteoporosis and inflammation. Nutr Rev. 2007;65(12 Pt 2):S147-51.
2. Romas E, Gillespie MT, Martin T. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone. 2002;30:340-6.
3. Teitelbaum SL. Osteoclasts: what do they do and how do they do it? Am J Pathol. 2007;170(2):427-35.
4. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under suitable microenvironment prepared by bone marrowderived stromal cells. Proc Natl Acad Sci U S A. 1990;87:7260-4.
5. Gillespie MT. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther. 2007;9:103.
6. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev. 2005;208:154-68.
7. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy. 2005;4(3):325-8.
8. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128(2):127-37.
9. Gregório LH, Lacativa PG, Melazzi AC, Russo LA. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metab. 2006;50(4):793-801.
10. Viswanathan A, Sylvester FA. Chronic pediatric inflammatory diseases: effects on bone. Rev Endocr Metab Disord. 2008;9(2):107-22.
11. Rodríguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J Gastroenterol. 2007;13(46):6156-65.
12. Roldán JF, Del Rincón I, Escalante A. Loss of cortical bone from the metacarpal diaphysis in patients with rheumatoid arthritis: independent effects of systemic inflammation and glucocorticoids. J Rheumatol. 2006;33(3):508-16.
13. Seriolo B, Ferretti V, Sulli A, Caratto E, Fasciolo D, Cutolo M. Serum osteocalcin levels in premenopausal rheumatoid arthritis patients. Ann N Y Acad Sci. 2002;966:502-7.
14. Lane NE. Therapy Insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2(10):562-9.
15. Borba VZ, Matos PG, Silva Viana PR, et al. High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus. 2005;14(7):529-33.
16. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD. Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus. 2004;13(6):436-41.
17. Borba VZC, Vieira JGH, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int. 2009;20(3):427-33.
18. Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599-604.
19. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):416-23.
20. Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can J Gastroenterol. 2007;21(10):637-42.
21. Souza HN, Lora FL, Kulak CAM, Mañas NCP, Amarante HMB, Borba VZC. Low levels of 25-hydroxyvitamin D (25OHD) in patients with inflammatory bowel disease and its correlation with bone mineral density. Arq Bras Endocrinol Metab. 2008;52(4):684-91.
22. Ashcroft AJ, Cruickshank SM, Croucher PI, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003;19:849-61.
23. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-9.
24. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl V):v1-16.
25. Reffitt DM, Meenan J, Sanderson JD, et al. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15(12):1267-73.
26. Cashman KD. Altered bone metabolism in inflammatory disease: role for nutrition. Proc Nutr Soc. 2008;67(2):196-205.
27. Elborn JS. How can we prevent multisystem complications of cystic fibrosis? Semin Respir Crit Care Med. 2007;28(3):303-11.
28. Shead EF, Haworth CS, Gunn E, Bilton D, Scott MA, Compston JE. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006;174(3):306-11.
29. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(12):1259-65.
30. Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res. 2006;7:70.
31. McEvoy CE, Ensrud KE, Bender E, et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:704-9.
32. Dam TT, Harrison S, Fink HA, Ramsdell J, Barrett-Connor E; for the Osteoporotic Fractures in Men (MrOS) Research Group. Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos Int. Epub 2009 Oct 9.
33. Lacativa PG, de Farias ML. Office practice of osteoporosis evaluation. Arq Bras Endocrinol Metab. 2006;50(4):674-84.
34. 2007 ISCD Official Positions. Available from: http://www.iscd.org/Visitors/pdfs/ISCD2007OfficialPositions-Combined-Adu ltandPediatric.pdf
35. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44(7):1496-503.
36. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005;90(3):1888-96.
37. van Hoorn JH, Hendriks JJ, Vermeer C, Forget PP. Vitamin K supplementation in cystic fibrosis. Arch Dis Child. 2003;88 (11):974-5.
38. Hardin DS, Sy JP. Effects of growth hormone treatment in children with cystic fibrosis: the National Cooperative Growth Study experience. J Pediatr. 1997;131(1 Pt 2):S65-9.
39. Hardin DS, Ahn C, Prestidge C, Seilheimer DK, Ellis KJ. Growth hormone improves bone mineral content in children with cystic fibrosis. J Pediatr Endocrinol Metab. 2005;18(6):589-95.
40. Hardin DS, Adams-Huet B, Brown D, et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab. 2006;91(12):4925-9.
41. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74(1):32-8.
42. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology. 2000;119:639-46.
43. Henderson S, Hoffman N, Prince R. A double-blind placebo controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol. 2006;101:119-23.
44. Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther. 2003;18:1121-7.
45. Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand J Gastroenterol. 2006;41:200-4.
46. McClung M. Role of RANKL inhibition in osteoporosis. Arthritis Res Ther. 2007;9(Suppl 1):S3.
47. Lane NE, Iannini M, Atkins C, et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:S225.
48. Dore R, Hurd E, Palmer W, et al. Denosumab increases bone mineral density in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:S240.
49. Cohen SB, Valen P, Ritchlin CT, et al. RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results. Arthritis Rheum. 2006;54:S831.
50. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis. 1989;48:396-9.
51. Maccagno A, Di Giorgio E, Roldan EJ, Caballero LE, Perez Lloret A. Double blind radiological assessment of continuous oral pamidronic acid in patients with rheumatoid arthritis. Scand J Rheumatol. 1994;23:211-4.
52. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 1996;39:396-402.
53. Ryan BM, Russel MGV, Schurgers L, et al. Effect of antitumour necrosis factor - a therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851-7.
54. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-5.
55. Brown MA. Antibody treatments of inflammatory arthritis. Curr Med Chem. 2005;12(25):2943-6.
56. Krause KH, Clark RA. Geneva Biology of Ageing Workshop 2000: phagocytes, inflammation, and ageing. Exp Gerontol. 2001;36(2):373-81.